Elsevier

Clinics in Liver Disease

Volume 15, Issue 4, November 2011, Pages 699-715
Clinics in Liver Disease

Transplantation for Cholangiocarcinoma

https://doi.org/10.1016/j.cld.2011.08.004Get rights and content

Section snippets

Risk factors

Although most cases of CCA arise in patients without an identifiable risk factor (ie, de novo CCA), several risk factors for the development of CCA have been identified, with chronic biliary inflammation being a common feature shared by many of them. Primary sclerosing cholangitis (PSC) is the most common identifiable risk factor in Western countries. The incidence of CCA in patients with PSC is 0.6% to 1.5% per year.6, 7 The lifetime risk of developing CCA in patients with PSC is between 7%

Pathophysiology and classification

Greater than 90% of CCAs are adenocarcinomas.18 Typically CCA is a well-differentiated to moderately differentiated adenocarcinoma with a prominent, dense, desmoplastic stroma (Fig. 1). This stroma leads to annular thickening of the bile duct caused by the infiltration and fibrosis of the periductal tissues. The large amount of fibrous stroma greatly increases the difficulty in confirming CCA by cytology and biopsy. Uncommon histologic variants include papillary adenocarcinoma, squamous cell,

Chemotherapy

Several chemotherapeutic regimens have been used in the treatment of CCA. However, the currently available chemotherapeutic or radiation therapy regimens only affect a modest improvement in patient survival. Most studies are difficult to interpret because of the small numbers of patients in each series and the inclusion of other neoplasms, such as gallbladder, pancreas, or hepatocellular carcinoma, which likely have a different response. Several regimens have used infusional 5-fluorouracil

Surgical resection

Surgical resection provides the only potential curative therapy for CCA. Unfortunately, CCA usually presents late in the disease course, and most patients have unresectable disease at presentation. Criteria for unresectability include distant lymph node or liver metastases; predicted inadequate function in the liver remnant; and bilobar involvement, including bilateral hepatic duct involvement of the secondary biliary radicals or atrophy of one lobe of the liver with encasement of the

Liver transplantation

Initial experiences with orthotropic liver transplantation (OLT) for unresectable CCA were disappointing because of the frequent recurrence of CCA. The 5-year survival rate was only 5% to 15% in these early studies.51, 52 However, there were some long-term survivors among patients with negative surgical resection margins and negative regional lymph nodes.53 This finding prompted the development of a protocol at the University of Nebraska and Mayo Clinic for neoadjuvant chemoradiation followed

Summary

CCA is a rare malignancy that arises from malignant transformation of the cells that line the biliary tree. The incidence of CCA is increasing globally. Primary sclerosing cholangitis and other conditions with chronic inflammation of the biliary tree are risk factors for the development of CCA. Hilar CCA usually presents with obstructive jaundice. Diagnostic techniques have significantly improved in the past 2 decades, enabling more accurate and less-invasive evaluation. Surgical resection and

First page preview

First page preview
Click to open first page preview

References (59)

  • G. Klatskin

    Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. An unusual tumor with distinctive clinical and pathological features

    Am J Med

    (1965)
  • M. De Bellis et al.

    Tissue sampling at ERCP in suspected malignant biliary strictures (part 1)

    Gastrointest Endosc

    (2002)
  • T.H. Baron et al.

    A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures

    Clin Gastroenterol Hepatol

    (2004)
  • B. Clary et al.

    Hilar cholangiocarcinoma

    J Gastrointest Surg

    (2004)
  • J.C. Nichols et al.

    Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis

    Mayo Clin Proc

    (1993)
  • B. Gruenberger et al.

    Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study

    Lancet Oncol

    (2010)
  • S. Iwatsuki et al.

    Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation

    J Am Coll Surg

    (1998)
  • M. Shimoda et al.

    Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature

    Liver Transpl

    (2001)
  • D. Sudan et al.

    Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma

    Am J Transplant

    (2002)
  • G.D. De Palma et al.

    Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study

    Gastrointest Endosc

    (2001)
  • T. Patel

    Worldwide trends in mortality from biliary tract malignancies

    BMC Cancer

    (2002)
  • Y. Shaib et al.

    The epidemiology of cholangiocarcinoma

    Semin Liver Dis

    (2004)
  • K. Burak et al.

    Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis

    Am J Gastroenterol

    (2004)
  • U. Broome et al.

    Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis

    Gut

    (1996)
  • C.B. Rosen et al.

    Cholangiocarcinoma complicating primary sclerosing cholangitis

    Ann Surg

    (1991)
  • N. Chalasani et al.

    Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study

    Hepatology

    (2000)
  • H.R. Shin et al.

    Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea

    Int J Epidemiol

    (1996)
  • J.P. Mecklin et al.

    The association between cholangiocarcinoma and hereditary nonpolyposis colorectal carcinoma

    Cancer

    (1992)
  • S.S. Lee et al.

    Clinicopathologic review of 58 patients with biliary papillomatosis

    Cancer

    (2004)
  • View full text